Entries by melindaroberts

How to Treat Uveal Melanoma that Recurs in the Liver?

A Q&A with Emma Shtivelman, PhD, Chief Scientist at Cancer Commons; emma@cancercommons.org Q: Malignant melanoma may arise from multiple sites, including the eye. What would you recommend be done for a 50-year-old man in the San Francisco Bay Area who was entirely well for nine years after undergoing enucleation surgery for a large uveal melanoma, but has […]

The Importance of Brain Tumor-Initiating Cells in Glioblastoma

A Q&A with Anita Hjelmeland, PhD, Associate Professor of Cell, Developmental and Integrative Biology at the University of Alabama Birmingham School of Medicine Q: The inner workings of malignant gliomas are mysterious to many of us. Why does the prognosis of patients with these tumors remain poor? A: Glioblastoma is a primary brain tumor that is […]

Navigating Pancreatic Cancer—The Basics

A Q&A with Lola Rahib, PhD, Lead Scientist, Pancreas Cancer, at Cancer Commons, Los Altos, CA Q: Navigating a pancreatic cancer diagnosis can be overwhelming and confusing for patients and their loved ones. How can patients and their caregivers ensure having the knowledge, support, and plan they need to be able to navigate treatment options […]

Ninth Annual Lundberg Institute Lecture

Achieving Quality of Health Care—Looking Back, Moving Forward The annual Lundberg Institute Lecture welcomes Kenneth W Kizer, MD, MPH, Chief Healthcare Transformation Officer and Senior Executive Vice President at Atlas Research, Inc., based in Washington, DC as the 9th annual Lundberg Lecturer. This year, the Lecture will be on October 9, 2019. Abstract In this […]

Serious Caveats in Screening for Pancreatic Cancer

A Q&A with Rama Gullapalli, MD, PhD; a a physician-scientist in the departments of Pathology, Chemical and Biological Engineering at the University of New Mexico. His research lab focuses on the role of the environment in hepatobiliary cancers. He is also a practicing molecular pathologist with an interest in emerging molecular diagnostics, next generation sequencing […]

Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part Three

A Q&A with Mark Shapiro, PhD,Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com. This is the final installment in a three-part series in which Dr. Shapiro has shared his thoughts on the question below. Read part 1 and part 2. Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater […]

Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part Two

A Q&A with Mark Shapiro, PhD,Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com. Last week, Dr. Shapiro shared his initial thoughts on the question below. Today, he discusses issues of cost and equitable access to care. Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater participation of such […]

Encouraging and Paying for Clinical Trials, Right to Try, and Expanded Access: Part One

A Q&A with Mark Shapiro, PhD,Vice President of Clinical Development at xCures, Inc., Partner at Pharma Initiatives; mshapiro@xcures.com Q: Treatment of Americans with advanced cancer is complex and challenging and can be very expensive. Many urge greater participation of such patients in clinical trials. In general, who pays the expenses of clinical trials? And, specifically, how are the costs for Right […]